What Researchers Did
Researchers conducted a retrospective single-center study to describe the characteristics, risk factors, and treatments of hemorrhagic cystitis in pediatric patients who underwent allogeneic hematopoietic stem cell transplantation between January 2007 and December 2022.
What They Found
Hemorrhagic cystitis (HC) occurred in 24 patients (14.7%) with a median onset of 27.5 days post-transplant. Acute graft-versus-host disease was significantly associated with HC occurrence (45.8% vs. 19.4%), and BK virus was detected in 66.7% of HC cases. Cidofovir was administered to 79.2% of patients, and severe cases required multimodal treatments like hyperbaric oxygen therapy (37.5%) and arterial embolization for all Grade 4 cases.
What This Means for Canadian Patients
Canadian pediatric patients undergoing hematopoietic stem cell transplantation may experience hemorrhagic cystitis, a significant complication that can prolong hospitalization. Understanding risk factors like acute graft-versus-host disease and implementing multimodal treatment approaches, including cidofovir and hyperbaric oxygen therapy for severe cases, can help manage this condition.
Canadian Relevance
This study was conducted at a single center outside of Canada, therefore its direct Canadian relevance is limited.
Study Limitations
The retrospective, single-center design limits the generalizability of these findings to broader pediatric populations.